ML Models Built Using Clinical Parameters and Radiomic Features Extracted from

18F-choline PET biochemical recurrence machine learning metastasis-directed therapy (MDT) prostate cancer radiomics

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
15 Jun 2024
Historique:
received: 16 05 2024
revised: 09 06 2024
accepted: 12 06 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Oligometastatic patients at [ Oligorecurrent patients (≤5 lesions) at A total of 46 metastases were selected and segmented in 29 patients. BCR after MDT occurred in 20 (69%) patients after 2 years of follow-up. In total, 73 and 33 robust RFTs were selected from CT and PET datasets, respectively. PET ML Models showed better performances than CT Models for discriminating BCR after MDT, with Stochastic Gradient Descent (SGD) being the best model (AUC = 0.95; CA = 0.90). ML Models built using clinical parameters and CT and PET RFts extracted via

Identifiants

pubmed: 38928679
pii: diagnostics14121264
doi: 10.3390/diagnostics14121264
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Luca Urso (L)

Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.

Corrado Cittanti (C)

Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.

Luigi Manco (L)

Medical Physics Unit, University Hospital of Ferrara, 44124 Ferrara, Italy.

Naima Ortolan (N)

Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.

Francesca Borgia (F)

Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.

Antonio Malorgio (A)

U.O.C. Radiotherapy, University Hospital of Ferrara, 44124 Ferrara, Italy.

Giovanni Scribano (G)

Department of Physics and Earth Science, University of Ferrara, 44121 Ferrara, Italy.

Edoardo Mastella (E)

Medical Physics Unit, University Hospital of Ferrara, 44124 Ferrara, Italy.

Massimo Guidoboni (M)

Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
U.O.C. Clinical Oncology, University Hospital of Ferrara, 44124 Ferrara, Italy.

Antonio Stefanelli (A)

U.O.C. Radiotherapy, University Hospital of Ferrara, 44124 Ferrara, Italy.

Alessandro Turra (A)

Medical Physics Unit, University Hospital of Ferrara, 44124 Ferrara, Italy.

Mirco Bartolomei (M)

Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.

Classifications MeSH